Skip to main content

Table 2 Factors associated with MVC prescription after a tropism test

From: Clinical impact of tropism testing in a real-life cohort of HIV infected patients: a retrospective observational study

 

Factors associated with MVC prescription

Univariate

Multivariate

OR (CI 95%)

p

OR (CI 95%)

p

Period of test:

Before 2011

4.16 (2.51–6.89)

< 0.01

3.65 (2.17–6.13)

< 0.01

After 2011

1

 

1

 

Age (years):

 

0.26

  

< 35

0.60 (0.25–1.45)

   

35–43

0.68 (0.35–1.32)

   

44–51

1.1 (0.63–1.93)

   

> 51

1

   

Time between ART initiation and tropism (years):

 

0.03

  

< 5

0.50 (0.27–0.92)

   

5–10

0.88 (0.49–1.58)

   

> 10

1

   

Number of previous ART regimens:

 

< 0.01

  

< 4

0.24 (0.11–0.51)

 

0.34 (0.15–0.74)

< 0.01

4–5

0.25 (0.11–0.55)

 

0.32 (0.14–0.74)

< 0.01

6–10

0.39 (0.19–0.79)

 

0.46 (0.22–0.97)

0.04

> 10

1

 

1

 

CD4 count (/mm3):

 

0.02

  

≤200

0.34 (0.13–0.85)

   

201–500

0.86 (0.52–1.42)

   

> 500

1

   

Reason for tropism performance:

    

Virological failure

1.95 (1.20–3.16)

< 0.01

1.10 (0.62–1.98)

0.73

Other

1

 

1

 
  1. MVC Maraviroc, ART Anti Retroviral Therapy